Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 3;25(5):1117-1124.
doi: 10.1016/j.ymthe.2017.03.034. Epub 2017 Apr 26.

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective

Isabelle Rivière  1 , Michel Sadelain  2
Affiliations
Review

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective

Isabelle Rivière et al. Mol Ther. .

Abstract

Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T lymphocytes to target chosen antigens. The targeting of CD19, a cell surface molecule expressed in the vast majority of leukemias and lymphomas, has been successfully translated in the clinic, earning CAR therapy a special distinction in the selection of "cancer immunotherapy" by Science as the breakthrough of the year in 2013. CD19 CAR therapy is predicated on advances in genetic engineering, T cell biology, tumor immunology, synthetic biology, target identification, cell manufacturing sciences, and regulatory compliance-the central tenets of CAR therapy. Here, we review two of these foundations: the genetic engineering approaches and cell types to engineer.

Keywords: CAR; T cells; genetic engineering; genome editing; immunotherapy; vectors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Assembling a CAR CAR therapy is predicated on cell engineering and the convergence of multiple disciplines and technologies.
See this image and copyright information in PMC

References

    1. Eshhar Z., Bach N., Fitzer-Attas C.J., Gross G., Lustgarten J., Waks T., Schindler D.G. The T-body approach: potential for cancer immunotherapy. Springer Semin. Immunopathol. 1996;18:199–209. - PubMed
    1. Sadelain M., Rivière I., Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer. 2003;3:35–45. - PubMed
    1. Irving B.A., Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64:891–901. - PubMed
    1. Romeo C., Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. 1991;64:1037–1046. - PubMed
    1. Letourneur F., Klausner R.D. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl. Acad. Sci. USA. 1991;88:8905–8909. - PMC - PubMed

MeSH terms